Tag Archives: ML8500

Modulight Spotlights: LASER-SHARP RESEARCH – October 2024

October 24, 2024 by Modulight Content
No comments
Modulight Spotlights: LASER-SHARP RESEARCH – October 2024 This month, we are highlighting new findings published in RSC Materials Advances by Olga Lem, Roosa Kekki and researchers at Pharmaceutical Nanotechnology research group and Tampere University. The study provides key insights into the role of lipid oxidation in cargo release from light-activated liposomes. These spherical lipid vesicles can be controlled by light to provide time- and site-specific drug delivery, for example for cancer treatment. Red light provides a non-invasive, selective, and safe trigger for releasing liposomal cargo. Modulight’s Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – September 2024

September 23, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – September 2024 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential Continue reading →

Ru(II) Oligothienyl Complexes with Fluorinated Ligands: Photophysical, Electrochemical, and Photobiological Properties

May 10, 2024 by Modulight Content
No comments
Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland  Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland A series of Ru(II) complexes were characterized and assessed for phototherapy effects toward cancer cells. Also activity in hypoxia was evaluated, with some of the compounds retaining partial activity in hypoxia. ML8500 was used for dosimetry studies, assessing impact of irradiance on the phototoxicity of Ru-4T with several different wavelengths. LEDs were used for Continue reading →

Development of thermosensitive liposomes with the help of ML8500

March 13, 2024 by Modulight Content
No comments
Background The proper delivery and release of therapeutic drugs to a specific site or cell type is one of the main challenges in the treatment of diseases. Liposomes, which are vesicles composed of lipids, serve as carriers for drug delivery thanks to their long circulation time. This results to reduced toxicity in healthy tissues and improved therapeutic efficacy of encapsulated drugs. However, conventional liposomes can often be even too stabile, leading to insufficient drug release at the target site. Light activation can offer a solution Continue reading →Customer case Pharmaceutical Nanotechnology Group at University of Helsinki is specialized in top-level pharmaceutical research. Led by Professor Timo Laaksonen, the group focuses on controlled drug release and delivery using modern methods and materials. Particular interest lies in using light to both monitor nanomaterial behavior and to trigger e.g. drug release processes. Modulight products: ML8500, ML6600, MLAKIT   Prof. Timo Laaksonen Dr. Tatu Lajunen Laser use: Light-triggered drug release studies from light-activated liposomes. ML8500 with 808 nm wavelength was used to induce the release of calcein from liposomes under Continue reading →

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids

February 6, 2024 by Modulight Content
No comments
Published in: Cell & Bioscience Authors: Aaron Sorrin, Anika Dasgupta, Kathryn McNaughton, Carla Arnau Del Valle, Keri Zhou, Cindy Liu, Dana M. Roque & Huang Chiao Huang Within the last decade, poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged in the clinic as an effective treatment for numerous malignancies. Preclinical data have demonstrated powerful combination effects of PARPi paired with photodynamic therapy (PDT), which involves light-activation of specialized dyes (photosensitizers) to stimulate cancer cell death through reactive oxygen species generation. In this study, a novel combination strategy was Continue reading →

Development of Robust Cationic Light-Activated Thermosensitive Liposomes: Choosing the Right Lipids

October 24, 2023 by Modulight Content
No comments
Published in: Molecular Pharmaceutics Authors: Puja Gangurde, Mohammad Mahmoudzadeh, Zahra Gounani, Artturi Koivuniemi, Patrick Laurén, Tatu Lajunen, Timo Laaksonen  Published in: Molecular Pharmaceutics Authors: Puja Gangurde, Mohammad Mahmoudzadeh, Zahra Gounani, Artturi Koivuniemi, Patrick Laurén, Tatu Lajunen, Timo Laaksonen The study investigated the impact of different lipids on liposome stability. It was found that substituting unsaturated lipid with equal amount of saturated lipid, resulted in stable liposomes that were highly responsive to light triggered release. ML8500 was used for light-activated release of calcein from liposomes.   Read the article here

Light-induced cytotoxicity in cells utilizing an automated well plate illuminator

March 7, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Johannes Kivelä, Lasse Orsila, Petteri Uusimaa    Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Johannes Kivelä, Lasse Orsila, Petteri Uusimaa   Delivering therapeutic drug molecules to the target site and releasing the cargo site-specifically is of major interest in biomedicine. To carry and release drugs to specific target tissues, different nanotechnology approaches have been utilized. These include light-sensitive liposomal carriers, which have been engineered to release cargo from their aqueous cores when illuminated by certain wavelengths of laser light. To study drug release parameters in vitro, Modulight Continue reading →

A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity

November 23, 2022 by Modulight Content
No comments
Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada    Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada   The study investigated HSP90-targeted PDT for minimally invasive treatment of ductal carcinoma in situ (DCIS), benign breast cancer condition that has potential to progress into breast cancer. PDT with ML8500 combined to ML7710 resulted in effective in vitro cytotoxicity and with ML7710 in vivo, which was further potentiated with PD-L1 immune checkpoint inhibitors.   Read the article Continue reading →

Light-activated drug release using an automated well plate illuminator

March 4, 2022 by Modulight Content
No comments
Presented in: SPIE BIOS 2022 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Lasse Orsila, Modulight Corporation (Finland), Tampere Univ. Hospital (Finland); Petteri Uusimaa, Modulight Corporation (Finland)    Presented in: SPIE BIOS 2022 Authors: Laura Vesala, Robert Perttilä, Elias Kokko, Lasse Orsila, Modulight Corporation (Finland), Tampere Univ. Hospital (Finland); Petteri Uusimaa, Modulight Corporation (Finland) Efficient site-specific delivery of systemic therapeutic drugs is crucial especially in oncology but has proved to be challenging. Drugs can be encapsulated into liposomes that offer improved therapeutic index and distribution of the drug. The release of the drug can be efficiently achieved by integrating light-sensitive component into liposomes and applying near-infrared light in a time- and site-specific manner. Continue reading →

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer

May 17, 2021 by Modulight Content
No comments
Motivation of the study In photodynamic therapy (PDT), systemically administered photosensitizer is activated within the tumor using focused near-infrared light, typically a laser with a wavelength matching the absorption peak of the photosensitizer. Several photosensitizers have been clinically approved for the treatment of different cancers; however, their accumulation is non-tumor exclusive which exposes healthy tissues to side effects like daylight-induced phototoxicity. A promising strategy to improve tumor selectivity is to couple photosensitizer to a tumor-targeting agent that binds to a specific antigen expressed on the Continue reading →Customer case Research by: Duke University, founded in 1924, is one of the leading and wealthiest private research universities in the USA. The most notable Duke alumni is President Richard Nixon. Research at Duke University has been awarded with several Nobel prizes in recent years for groundbreaking discoveries in biochemistry and medicine, such as G-protein coupled receptors, DNA mismatch repair, and cellular regulation of hypoxia. Modulight products: ML8500, ML7710 (665 nm, 689 nm, 750 nm) Laser use: Heat shock protein 90-targeted PDT for breast cancer Continue reading →